ASCO: Longer Tx Lengthens Life in GIST (CME/CE)
CHICAGO (MedPage Today) — Extending adjuvant imatinib (Gleevec) treatment for high-risk gastrointestinal stromal tumors (GIST) substantially boosts survival, researchers found.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com